Bicara Therapeutics Inc.
Business
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional therapies targeting solid tumors. The company's lead program, ficerafusp alfa, combines an EGFR-directed monoclonal antibody with a TGF-β ligand trap to enhance tumor penetration and modulate the immune microenvironment. Ficerafusp alfa is being evaluated in head and neck squamous cell carcinoma and other solid tumor types through Phase 1/1b trials and the FORTIFI-HN01 Phase 2/3 pivotal trial.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| General and administrative | 31 | 19 | 9 | |
| Total operating expenses | 156 | 82 | 40 | |
| Loss from operations | −156 | −82 | −40 | |
| Interest income | 18 | 15 | 1 | |
| Total other income, net | 18 | 15 | −12 | |
| Net loss before income taxes | −138 | −68 | −52 | |
| Income tax expense | −217,000 | −187,000 | — | |
| Net loss | −138 | −68 | −52 | |
| Net Loss per share, basic (in usd per share) | −2.52 | −4.05 | −89.61 | |
| Net Loss per share, diluted (in usd per share) | −2.52 | −4.05 | −89.61 | |
| Weighted-average number common shares outstanding, basic (in shares) | 54,677 | 16,806 | 580 | |
| Weighted-average number common shares outstanding, diluted (in shares) | 54,677 | 16,806 | 580 | |
| Unrealized gain on marketable securities, net of tax | 243,000 | 0 | — | |
| Total other comprehensive income | 243,000 | 0 | — | |
| Total comprehensive loss | −138 | −68 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 97 | 490 | 230 | — | |
| Prepaid expenses and other assets | 7 | 13 | 633,000 | — | |
| Marketable securities | 318 | 0 | — | — | |
| Total current assets | 422 | 503 | 231 | — | |
| Property and equipment, net | 330,000 | 155,000 | 202,000 | — | |
| Right of use asset operating lease | 2 | 690,000 | 613,000 | — | |
| Other assets | 7 | 7 | 2 | — | |
| Total assets | 431 | 510 | 234 | — | |
| Operating lease liability current portion | 1 | 607,000 | 285,000 | — | |
| Total current liabilities | 29 | 18 | 15 | — | |
| Operating lease liability net of current portion | 593,000 | 131,000 | 372,000 | — | |
| Total liabilities | 30 | 18 | 15 | — | |
| Commitments and Contingencies (Note 7) | — | — | — | — | |
| Preferred stock $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | — | |
| Common stock, $0.0001 par value, 500,000,000 shares authorized; 56,600,724 and 54,444,180 shares issued and 56,600,724 and 54,440,013 shares outstanding as of December 31, 2025 and December 31, 2024, respectively | 7,000 | 7,000 | 2,000 | — | |
| Additional paid-in capital | 760 | 713 | 4 | — | |
| Accumulated other comprehensive gain | 243,000 | 0 | — | — | |
| Accumulated deficit | −359 | −221 | −153 | — | |
| Total stockholders' equity | 401 | 492 | −149 | −99 | |
| Total liabilities and stockholders equity | 431 | 510 | 234 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Stock-based compensation | 15 | 7 | 2 | |
| Depreciation | 105,000 | 56,000 | 19,000 | |
| Non-cash lease expense | 895,000 | −77,000 | 90,000 | |
| Net amortization of premiums and discounts on marketable securities | 301,000 | 0 | — | |
| Prepaid expenses and other assets | 5 | −17 | −914,000 | |
| Operating lease liabilities | −932,000 | 81,000 | −47,000 | |
| Net cash used in operating activities | −107 | −75 | −46 | |
| Purchases of marketable securities | −318 | 0 | — | |
| Purchase of property and equipment | −280,000 | −71,000 | −586,000 | |
| Proceeds from sale of property and equipment | 0 | 62,000 | 0 | |
| Net cash used in investing activities | −318 | −9,000 | −586,000 | |
| Proceeds from issuance on common stock, net of issuance costs | 29 | 332 | 0 | |
| Proceeds from exercise of options | 3 | 2 | 149,000 | |
| Net cash provided by financing activities | 32 | 334 | 272 | |
| Net increase (decrease) in cash and cash equivalents | −393 | 259 | 226 | |
| Right-of-use asset obtained in exchange for lease liability | 2 | 413,000 | 703,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Bicara Therapeutics Inc.'s CIK number?
Bicara Therapeutics Inc.'s SEC CIK number is 0002023658 (2023658). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Bicara Therapeutics Inc.'s SEC filings?
All of Bicara Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Bicara Therapeutics Inc. last report earnings?
Bicara Therapeutics Inc. (BCAX) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-033135). This is Bicara Therapeutics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Bicara Therapeutics Inc.'s most recent earnings 8-K?
Bicara Therapeutics Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001628280-26-033135. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Bicara Therapeutics Inc.'s latest earnings 8-K →
Look up any company's CIK number →